Mammalian cell membranes provide an interface between the intracellular and extracellular compartments. It is currently thought that cytoplasmic signaling adapter proteins play no functional role within the extracellular tumor environment. Here, by selecting combinatorial random peptide libraries in tumor-bearing mice, we uncovered a direct, specific, and functional interaction between CRKL, an adapter protein [with Src homology 2 (SH2)-and SH3-containing domains], and the plexin-semaphorin-integrin domain of 1 integrin in the extracellular milieu. Through assays in vitro, in cellulo, and in vivo, we show that this unconventional and as yet unrecognized proteinprotein interaction between a regulatory integrin domain (rather than a ligand-binding one) and an intracellular adapter (acting outside of the cells) triggers an alternative integrin-mediated cascade for cell growth and survival. Based on these data, here we propose that a secreted form of the SH3/SH2 adaptor protein CRKL may act as a growth-promoting factor driving tumorigenesis and may lead to the development of cancer therapeutics targeting secreted CRKL.cancer ͉ CrkL ͉ integrin ͉ phage display C ell membranes have evolved as a tight and compartmentalized, but dynamic, interface between intracellular and extracellular contents (1, 2). To maintain such homeostasis, transmembrane receptors mediate bidirectional signaling across the cell surface through a complex spatial and temporal organization (3, 4). Thus, protein location in signal transduction is central to specificity of cellular responses (2,5,6). For example, cell surface receptors such as integrins undergo conformational changes elicited through ligand binding to enable a cross-talk with signal transduction cascades such as the MAPK pathways; conventional integrin ligands include ECM proteins that recognize integrin extracellular domains and cytoskeletal proteins that interact with intracellular domains (3-4, 7-9).To gain insight into signal transduction across cell membranes in cancer, we set out to identify functional protein interactions in a tumor xenograft model; we reasoned that a combinatorial approach (10-14) in vivo might provide clues by emulating ligand-receptor binding in the context of the tumor microenvironment. Here, we show a specific interaction between the intracellular signaling protein CRKL and a regulatory (rather than ligand-binding)  1 integrin extracellular domain. Surprisingly, we found that CRKL targets the plexin-semaphorin-integrin (PSI) domain of  1 integrin chain located outside of the cell and promotes cell growth and survival. These results indicate an unrecognized integrin-mediated outside-in function for intracellular mediators, such as Src homology 2 (SH2)-and SH3-containing proteins, in activating proliferative pathways.
Results
Combinatorial Selection in Vivo Yields Tumor-Homing Peptides.We administered a phage library (12,14,15) i.v. into nu/nu (nude) mice bearing human DU145-derived prostate cancer xenografts and recovered tumors after 24-h circulation. ...